Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOP-3: Intratesticular Testosterone and Sperm Production
NCT00839319Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2009
- Primary completion
- Sep 2010
- Countries
- 1
- Sponsor
- University of Washington
- Modality
- Peptides, Small Molecules
- Drugs
- acyline
- Conditions
- male contraception
01
Overview
Phase 2, randomised trial of acyline in male contraception (5 arms), sponsored by University of Washington. Primary endpoints: Serum Testosterone at 10 days, Serum Luteinizing Hormone at 10 days and 2 more. Started Mar 2009; status: completed.
02
Design
5 arms- Study design
- Randomized
Acyline + Placebo
Acyline 300 ug/kg SQ + Placebo hCG
Acyline + 15 IU hCG
Acyline 300 ug/kg SQ + 15 IU hCG
Acyline + 60 IU hCG
Acyline 300 ug/kg SQ + 60 IU hCG
Acyline + 125 IU hCG
Acyline 300 ug/kg SQ + 125 IU hCG
Acyline + Testosterone gel
Acyline 300 ug/kg SQ + Testosterone gel 75 mg/day
03
Who it enrols
Healthy males aged 18-50 with normal testosterone and sperm count, willing to use contraception.
04
Endpoints
Primary
Serum Testosterone
Serum Luteinizing Hormone
Serum Follicle Stimulating Hormone
Intratesticular Testosterone
Beyond the preview
Go deeper on NCT00839319.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00839319.